It also takes longer for stroke patients to fully recover when they have COVID-19.

The study, published in Stroke, focused on data from more than 16,000 pairs of twins born from 1958 to 1974.

“There is currently no standard of care for anticoagulation in hospitalized COVID-19 patients, and there is a desperate need for clinical evidence to guide practice,” one NIH official said. 

In a new analysis, researchers highlighted IVL’s potential for helping with the treatment of coronary artery disease.

The combination of inflammation and thrombosis is crucial, suggesting that endothelial dysfunction could be at the heart of this complex infection.

The team's analysis also examines why blood-thinning medications aren't effectively preventing the clots. 

Researchers detailed a method that improves patient safety and leads to significant cost savings.

This brand new guidance was published by the American Heart Association.

Blood substitution therapy removes inflammatory cells from the body, limiting some of the more extreme side effects associated with experiencing a stroke. 

Despite the improved outcomes, utilization of IVUS-guided PCI remains low and inconsistent.

The project includes a new technology research center at Boston University and support for scientists around the world.

Overall, the PCSK9 inhibitor was associated with a steady increase in coronary artery area and “significant coronary blood flow improvement.”